Postoperative Analgesia Impact of Narcotic Free Anesthesia (PAINFree)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01544959
Recruitment Status : Active, not recruiting
First Posted : March 6, 2012
Last Update Posted : October 27, 2016
Information provided by (Responsible Party):
Etienne de Medicis, Université de Sherbrooke

September 9, 2010
March 6, 2012
October 27, 2016
January 2010
January 2013   (Final data collection date for primary outcome measure)
Postoperative consumption of narcotic in recovery room [ Time Frame: Immediately after surgery ]
Same as current
Complete list of historical versions of study NCT01544959 on Archive Site
  • Pain level in recovery room [ Time Frame: immediately after surgery ]
  • Occurence of nausea and vomiting in the recovery room [ Time Frame: immediately after surgery ]
  • Time spent in recovery room [ Time Frame: immediately after surgery ]
  • Chronic post-surgical pain [ Time Frame: 3 and 6 months ]
  • Reccurence of breast cancer [ Time Frame: 5 years ]
Same as current
Not Provided
Not Provided
Postoperative Analgesia Impact of Narcotic Free Anesthesia
The Impact on Postoperative Pain of Substituting Opioids by Beta Blockers for Peroperative Hemodynamic Control in Patients Undergoing Mastectomy

The first hypothesis of the study is that substituting fentanyl by esmolol and metoprolol during general anesthesia for patients undergoing mastectomy will result in less pain and less narcotic consumption in the recovery room. The investigators will also verify the impact of that substitution on nausea and vomiting, on the time spent in the recovery room and on chronic postsurgical pain (3 and 6 months).

Finally, the investigators will see the impact on breast cancer recurrence 5 years after the surgery.

Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Pain, Postoperative
  • Breast Cancer
  • Postoperative Nausea and Vomiting
  • Drug: fentanyl
    Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
  • Drug: beta-blocker (esmolol, metropolol)
    esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
  • Active Comparator: fentanyl
    Intervention: Drug: fentanyl
  • Experimental: beta-blocker
    Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
    Intervention: Drug: beta-blocker (esmolol, metropolol)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Same as current
January 2018
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Woman
  • 18 to 65 years old
  • ASA 1 or 2
  • First breast surgery
  • Unilateral breast cancer
  • Partial mastectomy or radical modified mastectomy ± axillary dissection

Exclusion Criteria:

  • Allergy or contrindication to any medication figuring in the protocol or to Aspirin
  • Patient taking betablocking drug drug or lanoxin or calcic channels blocking drug
  • Narcotic consumption in the past month of 10 mg/day of morphine equivalent
  • Chronic pain
  • Moderate to severe asthma
  • BMI of more than 40
  • Diabetes
  • Chronic renal or hepatic faiure
  • Heart failure
  • Anticipated difficult airway
  • High grade heart block or bifascicular block
  • Mental retardation
Sexes Eligible for Study: Female
18 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
CAS-008-2010 ( Other Grant/Funding Number: CAS/Vitaid Award )
Not Provided
Not Provided
Etienne de Medicis, Université de Sherbrooke
Université de Sherbrooke
Not Provided
Principal Investigator: Etienne de Medicis, MD MSc Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Université de Sherbrooke
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP